PE20050755A1 - Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina - Google Patents

Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina

Info

Publication number
PE20050755A1
PE20050755A1 PE2004000963A PE2004000963A PE20050755A1 PE 20050755 A1 PE20050755 A1 PE 20050755A1 PE 2004000963 A PE2004000963 A PE 2004000963A PE 2004000963 A PE2004000963 A PE 2004000963A PE 20050755 A1 PE20050755 A1 PE 20050755A1
Authority
PE
Peru
Prior art keywords
composition
mycophenolic acid
rapamycin
multiparticles
combination
Prior art date
Application number
PE2004000963A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Becker
Carsten Burger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
Jorg Ogorka
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050755A1 publication Critical patent/PE20050755A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2004000963A 2003-10-03 2004-10-01 Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina PE20050755A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds

Publications (1)

Publication Number Publication Date
PE20050755A1 true PE20050755A1 (es) 2005-11-28

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000963A PE20050755A1 (es) 2003-10-03 2004-10-01 Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina

Country Status (11)

Country Link
US (1) US20070036857A1 (cg-RX-API-DMAC7.html)
EP (1) EP1670437A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007507458A (cg-RX-API-DMAC7.html)
AR (1) AR045957A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004280078B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414864A (cg-RX-API-DMAC7.html)
CA (1) CA2538099A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003646A (cg-RX-API-DMAC7.html)
PE (1) PE20050755A1 (cg-RX-API-DMAC7.html)
TW (1) TW200520759A (cg-RX-API-DMAC7.html)
WO (1) WO2005034916A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CN101378749A (zh) * 2006-02-13 2009-03-04 诺瓦提斯公司 高剂量的麦考酚酸(mpa)
US20080161335A1 (en) * 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
BRPI0816231A2 (pt) * 2007-08-13 2015-06-16 Panacea Biotec Ltd Composições de liberação prolongada compreendendo micofenolato de sódio e seus processos
EP2262483A2 (en) * 2008-03-05 2010-12-22 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
EP2446027A1 (en) * 2009-06-25 2012-05-02 Danisco A/S Protein
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2763663B1 (en) * 2011-10-06 2017-12-27 Novartis AG Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ,インコーポレイテッド ピロカルピンの医薬製剤
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事(everolimus)之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
MX2019010829A (es) * 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20250282721A9 (en) * 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
US20250327799A1 (en) * 2022-05-16 2025-10-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
PT721335E (pt) * 1993-10-01 2005-11-30 Roche Palo Alto Llc Suspensoes orais em altas doses de micofenolato de mofetil
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
EP1097705A2 (en) * 1996-10-14 2001-05-09 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
MXPA04006731A (es) * 2002-01-10 2004-10-04 Novartis Ag Sistema de administracion de farmacos que comprenden rapamicina y derivados de la misma para la prevencion y tratamiento de enfermedades vasculares.
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2005034916A1 (en) 2005-04-21
AU2004280078A1 (en) 2005-04-21
JP2007507458A (ja) 2007-03-29
CA2538099A1 (en) 2005-04-21
US20070036857A1 (en) 2007-02-15
MXPA06003646A (es) 2006-06-05
EP1670437A1 (en) 2006-06-21
TW200520759A (en) 2005-07-01
BRPI0414864A (pt) 2006-11-28
AR045957A1 (es) 2005-11-16
AU2004280078B2 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
PE20050755A1 (es) Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina
MX2009004439A (es) Composicion de ibuprofeno.
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
ECSP088239A (es) Composición de liberación de fármaco sostenida
WO2007070677A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
BR0209489A (pt) Composições farmacêuticas
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
CO6400186A2 (es) Tabletas de acetato de ulipristal
BR0210139A (pt) Composições farmacêuticas
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
DK1480624T3 (da) Farmaceutisk tablet
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
ECSP088240A (es) Composición de trazodona para administración una vez por día
BRPI0508063A (pt) processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
JP2009537554A5 (cg-RX-API-DMAC7.html)
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
MX2009003169A (es) Derivados de sulfonamida.
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
RU2008147216A (ru) Жидкая лекарственная композиция

Legal Events

Date Code Title Description
FX Voluntary withdrawal